Plasma Level of Soluble ST2 in Chronically Infected HIV-1 Patients with Suppressed Viremia
Mehwish Younas1, Christina Psomas1, 2, Vikram Mehraj3, Renaud Cezar4, Pierre Portales5, Edouard Tuaillon6, Adeline Guigues1, Jacques Reynes2, 7, 8, Pierre Corbeau1, 4, 8, *, †, Jean-Pierre Routy3, 9, †
Identifiers and Pagination:Year: 2017
First Page: 32
Last Page: 35
Publisher ID: TOAIDJ-11-32
Article History:Received Date: 06/11/2016
Revision Received Date: 20/01/2017
Acceptance Date: 24/01/2017
Electronic publication date: 26/04/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Interleukin-33 (IL-33) is a cell damage-induced alarmin. The plasma concentration of suppression of tumorogenicity (sST2), a surrogate marker of IL-33 production, is a prognostic marker of cardiovascular disease.
Recently, we reported that sST2 plasma levels were elevated in early HIV-1 infection and linked to markers of microbial translocation and of T cell activation.
Here we show that it is not the case in patients with suppressed viremia. Thus, IL-33 plays its alarmin role only during the early phase of the infection.